555 related articles for article (PubMed ID: 11451954)
21. Purification and activity assays for Ubc9, the ubiquitin-conjugating enzyme for the small ubiquitin-like modifier SUMO.
Yunus AA; Lima CD
Methods Enzymol; 2005; 398():74-87. PubMed ID: 16275321
[TBL] [Abstract][Full Text] [Related]
22. The binding interface between an E2 (UBC9) and a ubiquitin homologue (UBL1).
Liu Q; Jin C; Liao X; Shen Z; Chen DJ; Chen Y
J Biol Chem; 1999 Jun; 274(24):16979-87. PubMed ID: 10358047
[TBL] [Abstract][Full Text] [Related]
23. Ubc9p and the conjugation of SUMO-1 to RanGAP1 and RanBP2.
Saitoh H; Sparrow DB; Shiomi T; Pu RT; Nishimoto T; Mohun TJ; Dasso M
Curr Biol; 1998 Jan; 8(2):121-4. PubMed ID: 9427648
[TBL] [Abstract][Full Text] [Related]
24. Preferential interaction of sentrin with a ubiquitin-conjugating enzyme, Ubc9.
Gong L; Kamitani T; Fujise K; Caskey LS; Yeh ET
J Biol Chem; 1997 Nov; 272(45):28198-201. PubMed ID: 9353268
[TBL] [Abstract][Full Text] [Related]
25. Structures of the SUMO E1 provide mechanistic insights into SUMO activation and E2 recruitment to E1.
Lois LM; Lima CD
EMBO J; 2005 Feb; 24(3):439-51. PubMed ID: 15660128
[TBL] [Abstract][Full Text] [Related]
26. Modification of Ran GTPase-activating protein by the small ubiquitin-related modifier SUMO-1 requires Ubc9, an E2-type ubiquitin-conjugating enzyme homologue.
Lee GW; Melchior F; Matunis MJ; Mahajan R; Tian Q; Anderson P
J Biol Chem; 1998 Mar; 273(11):6503-7. PubMed ID: 9497385
[TBL] [Abstract][Full Text] [Related]
27. The mouse genome contains two expressed intronless retroposed pseudogenes for the sentrin/sumo-1/PIC1 conjugating enzyme Ubc9.
Tsytsykova AV; Tsitsikov EN; Wright DA; Futcher B; Geha RS
Mol Immunol; 1998 Nov; 35(16):1057-67. PubMed ID: 10068040
[TBL] [Abstract][Full Text] [Related]
28. Biochemical characterization of the small ubiquitin-like modifiers of Chlamydomonas reinhardtii.
Shin YC; Liu BY; Tsai JY; Wu JT; Chang LK; Chang SC
Planta; 2010 Aug; 232(3):649-62. PubMed ID: 20544217
[TBL] [Abstract][Full Text] [Related]
29. SUMO-1 conjugation to topoisomerase I: A possible repair response to topoisomerase-mediated DNA damage.
Mao Y; Sun M; Desai SD; Liu LF
Proc Natl Acad Sci U S A; 2000 Apr; 97(8):4046-51. PubMed ID: 10759568
[TBL] [Abstract][Full Text] [Related]
30. SUMO: getting it on.
Anckar J; Sistonen L
Biochem Soc Trans; 2007 Dec; 35(Pt 6):1409-13. PubMed ID: 18031233
[TBL] [Abstract][Full Text] [Related]
31. Viral control of the SUMO pathway: Gam1, a model system.
Chiocca S
Biochem Soc Trans; 2007 Dec; 35(Pt 6):1419-21. PubMed ID: 18031235
[TBL] [Abstract][Full Text] [Related]
32. Interaction of Daxx, a Fas binding protein, with sentrin and Ubc9.
Ryu SW; Chae SK; Kim E
Biochem Biophys Res Commun; 2000 Dec; 279(1):6-10. PubMed ID: 11112409
[TBL] [Abstract][Full Text] [Related]
33. An E3-like factor that promotes SUMO conjugation to the yeast septins.
Johnson ES; Gupta AA
Cell; 2001 Sep; 106(6):735-44. PubMed ID: 11572779
[TBL] [Abstract][Full Text] [Related]
34. SUMO conjugation and deconjugation.
Schwienhorst I; Johnson ES; Dohmen RJ
Mol Gen Genet; 2000 Jun; 263(5):771-86. PubMed ID: 10905345
[TBL] [Abstract][Full Text] [Related]
35. Ubc9 interacts with the androgen receptor and activates receptor-dependent transcription.
Poukka H; Aarnisalo P; Karvonen U; Palvimo JJ; Jänne OA
J Biol Chem; 1999 Jul; 274(27):19441-6. PubMed ID: 10383460
[TBL] [Abstract][Full Text] [Related]
36. In vitro modification of human centromere protein CENP-C fragments by small ubiquitin-like modifier (SUMO) protein: definitive identification of the modification sites by tandem mass spectrometry analysis of the isopeptides.
Chung TL; Hsiao HH; Yeh YY; Shia HL; Chen YL; Liang PH; Wang AH; Khoo KH; Shoei-Lung Li S
J Biol Chem; 2004 Sep; 279(38):39653-62. PubMed ID: 15272016
[TBL] [Abstract][Full Text] [Related]
37. Site-specific inhibition of the small ubiquitin-like modifier (SUMO)-conjugating enzyme Ubc9 selectively impairs SUMO chain formation.
Wiechmann S; Gärtner A; Kniss A; Stengl A; Behrends C; Rogov VV; Rodriguez MS; Dötsch V; Müller S; Ernst A
J Biol Chem; 2017 Sep; 292(37):15340-15351. PubMed ID: 28784659
[TBL] [Abstract][Full Text] [Related]
38. Ubc9 sumoylation regulates SUMO target discrimination.
Knipscheer P; Flotho A; Klug H; Olsen JV; van Dijk WJ; Fish A; Johnson ES; Mann M; Sixma TK; Pichler A
Mol Cell; 2008 Aug; 31(3):371-82. PubMed ID: 18691969
[TBL] [Abstract][Full Text] [Related]
39. Involvement of PIAS1 in the sumoylation of tumor suppressor p53.
Kahyo T; Nishida T; Yasuda H
Mol Cell; 2001 Sep; 8(3):713-8. PubMed ID: 11583632
[TBL] [Abstract][Full Text] [Related]
40. In vitro SUMO-1 modification requires two enzymatic steps, E1 and E2.
Okuma T; Honda R; Ichikawa G; Tsumagari N; Yasuda H
Biochem Biophys Res Commun; 1999 Jan; 254(3):693-8. PubMed ID: 9920803
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
